Skip to main content
. Author manuscript; available in PMC: 2017 Jan 13.
Published in final edited form as: Expert Rev Neurother. 2016 Jan 13;16(2):123–130. doi: 10.1586/14737175.2016.1134322

Figure 3. Pharmacokinetics of EP2 antagonist TG6-10-1.

Figure 3

(A) The chemical structure of compound TG6-10-1. (B) TG6-10-1 was administered to mice (5 mg/kg, i.p.) for pharmacokinetic studies. Compound concentrations in the plasma (ng/ml) and brain (ng/g) were measured at different time points. TG6-10-1 displayed a plasma terminal half-life of 1.6 h and brain/plasma ratio of 1.6. Data are shown as mean ± SEM (n = 3 mice per time point). The compound Schild KB values for 8 canonical prostanoid receptors were also indicated: 74.6, 762, 7.98, 2380, 7740, 202, 3640, and 193 ng/ml for DP1, EP1, EP2, EP3, EP4, FP, IP, and TP receptors, respectively. Modified from Jiang et al., 2013.